Anlotinib Hydrochloride: Multi-Target Tyrosine Kinase Inhibitor for Advanced Angiogenesis Research

Executive Summary: Anlotinib hydrochloride (CAS 1058157-76-8) is a novel small-molecule inhibitor targeting VEGFR2, PDGFRβ, and FGFR1, with nanomolar IC₅₀ values for each kinase (Lin et al., 2018). It significantly suppresses tumor angiogenesis by inhibiting endothelial cell migration and tube formation in vitro and in vivo (Lin et al., 2018). The compound demonstrates superior anti-angiogenic potency over sunitinib, sorafenib, and nintedanib under identical assay conditions (Lin et al., 2018). Anlotinib shows favorable pharmacokinetics, including high plasma protein binding and broad tissue distribution, supporting its research utility (APExBIO). APExBIO supplies validated Anlotinib (hydrochloride) (SKU C8688) for preclinical and mechanistic studies.

Biological Rationale

Angiogenesis is the physiological process involving the growth of new blood vessels from pre-existing vasculature (Lin et al., 2018). Tumor development and metastasis rely on angiogenesis to supply nutrients and oxygen (Lin et al., 2018). Key pro-angiogenic growth factors include vascular endothelial growth factor (VEGF), platelet-derived growth factor-BB (PDGF-BB), and fibroblast growth factor 2 (FGF-2), acting through their respective receptor tyrosine kinases, VEGFR2, PDGFRβ, and FGFR1 (Lin et al., 2018). Dysregulation of these pathways is a hallmark of many cancers (Lin et al., 2018).

Mechanism of Action of Anlotinib (hydrochloride)

Anlotinib hydrochloride is a multi-target tyrosine kinase inhibitor that potently blocks VEGFR2 (IC₅₀ = 5.6 ± 1.2 nM), PDGFRβ (IC₅₀ = 8.7 ± 3.4 nM), and FGFR1 (IC₅₀ = 11.7 ± 4.1 nM) in biochemical assays (Lin et al., 2018; APExBIO). It inhibits ligand-induced receptor phosphorylation, leading to downregulation of downstream ERK signaling (Lin et al., 2018). In endothelial cell models (EA.hy 926), anlotinib suppresses VEGF/PDGF-BB/FGF-2-driven migration and capillary-like tube formation in a concentration-dependent manner (Lin et al., 2018). This directly impedes neovascularization and tumor progression mechanisms.

Evidence & Benchmarks

• Anlotinib inhibits VEGF/PDGF-BB/FGF-2-induced migration of human endothelial cells (EA.hy 926) in vitro, with statistically significant reduction compared to controls (Lin et al., 2018).
• In tube formation assays, anlotinib reduces capillary-like structure formation with greater potency than sunitinib, sorafenib, and nintedanib, under matched experimental conditions (Lin et al., 2018).
• The compound suppresses blood vessel sprouting in rat aortic ring and chicken chorioallantoic membrane (CAM) assays, demonstrating in vivo anti-angiogenic activity (Lin et al., 2018).
• Pharmacokinetic studies show oral bioavailability of 28–58% in rats and 41–77% in dogs, with 93% plasma protein binding in humans (APExBIO).
• Toxicology studies reveal a median lethal dose (LD₅₀) of 1735.9 mg/kg after 14-day oral dosing in rodents, indicating low acute toxicity (APExBIO).

For further mechanistic insights, see this molecular analysis, which provides deeper discussion on ERK pathway modulation, extending this article's focus on comparative potency and workflow integration.

Applications, Limits & Misconceptions

Anlotinib hydrochloride is employed in cancer research to dissect mechanisms of tumor angiogenesis and evaluate anti-angiogenic strategies (Prescission, 2023). It is validated for use in cell migration, wound healing, and tube formation assays, particularly with human vascular endothelial cell lines (EA.hy 926) (Lin et al., 2018). The compound's multi-target profile makes it valuable for studies requiring simultaneous inhibition of VEGFR2, PDGFRβ, and FGFR1, especially in models of complex angiogenic signaling (Estragolecas, 2023). Researchers should note that anlotinib is for scientific research only and not approved for diagnostic or therapeutic use in humans (APExBIO).

Common Pitfalls or Misconceptions

• Anlotinib (hydrochloride) is not a selective single-target inhibitor; it affects multiple tyrosine kinases and may impact other pathways at high concentrations.
• It is not validated for use in clinical or diagnostic settings; in vivo studies must comply with ethical regulations and local jurisdictional guidelines.
• Results from rodent or avian models may not fully translate to human pathophysiology; direct extrapolation to clinical scenarios is not supported by preclinical data alone.
• The compound's efficacy and toxicity profiles may differ in non-endothelial or non-tumor contexts.
• Long-term genetic or developmental toxicity data in higher mammals are limited.

See Translational Horizons in Tumor Angiogenesis for a strategic perspective on experimental design and translational bottlenecks, complementing this article's focus on preclinical benchmarks and workflow integration.

Workflow Integration & Parameters

Anlotinib hydrochloride is supplied as a solid and should be stored at -20°C (APExBIO). For in vitro use, it is typically dissolved in DMSO and diluted in culture media for cell-based assays. Recommended concentration ranges for endothelial cell assays are 1–100 nM, depending on the target and desired inhibition level (Lin et al., 2018). Assays such as wound healing, chamber migration, and tube formation are validated in EA.hy 926 cells, with controls matched for vehicle and growth factor conditions. For in vivo research, dosing and ethical compliance must be strictly observed. For detailed research protocols and quality control documentation, consult the Anlotinib (hydrochloride) C8688 kit page from APExBIO.

For a molecular-level exploration of anti-angiogenic mechanisms, see this advanced resource, which elucidates translational applications, complementing this article's practical focus on integration into research workflows.

Conclusion & Outlook

Anlotinib hydrochloride is a validated, potent multi-target tyrosine kinase inhibitor for anti-angiogenic research, offering superior efficacy over established agents in preclinical models (Lin et al., 2018). Its robust inhibition of VEGFR2, PDGFRβ, and FGFR1, coupled with a favorable pharmacokinetic and safety profile, supports broad adoption in cancer and angiogenesis studies. Continued research will clarify its translational potential and refine its applications in next-generation experimental systems. For rigorously characterized, research-grade material, APExBIO's Anlotinib (hydrochloride) (SKU C8688) remains a preferred choice for preclinical study design and mechanistic exploration.